Cargando…
Is Tofacitinib Effectiveness in Patients with Rheumatoid Arthritis Better After Conventional Than After Biological Therapy? – A Cohort Study in a Colombian Population
PURPOSE: Tofacitinib is recommended for treatment of rheumatoid arthritis (RA) in patients with moderate to severe disease activity, but there is not enough evidence on its effectiveness after conventional DMARDs vs its use after biologics. The aim was evaluating the effectiveness of tofacitinib in...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289171/ https://www.ncbi.nlm.nih.gov/pubmed/35860386 http://dx.doi.org/10.2147/BTT.S361164 |
_version_ | 1784748604119842816 |
---|---|
author | Santos-Moreno, Pedro Martinez, Susan Ibata, Linda Villarreal, Laura Rodríguez-Florido, Fernando Rivero, Manuel Rojas-Villarraga, Adriana Galarza-Maldonado, Claudio |
author_facet | Santos-Moreno, Pedro Martinez, Susan Ibata, Linda Villarreal, Laura Rodríguez-Florido, Fernando Rivero, Manuel Rojas-Villarraga, Adriana Galarza-Maldonado, Claudio |
author_sort | Santos-Moreno, Pedro |
collection | PubMed |
description | PURPOSE: Tofacitinib is recommended for treatment of rheumatoid arthritis (RA) in patients with moderate to severe disease activity, but there is not enough evidence on its effectiveness after conventional DMARDs vs its use after biologics. The aim was evaluating the effectiveness of tofacitinib in RA as first-line treatment (after conventional DMARDs) in a real-life setting in Colombian (Latin-American) patients. PATIENTS AND METHODS: Retrospective cohort study conducted at a specialized center for RA management. A complete statistical analysis was performed to compare the values of the change in the DAS28 at months 3, 6, and 12 in both treatment groups. RESULTS: A total of 152 RA patients who received tofacitinib: first-line 85 patients (55.9%) after failure on conventional DMARDs or second-line 67 patients (44.1%) after failure on biologic DMARDs. Comparative analysis of response to treatment showed a reduction in DAS28 at 3, 6, and 12 months in both study groups without statistical differences, but a higher proportion of first-line patients achieved remission (45% vs 23%). Nonresponse at three months were associated with no response at six months of follow-up. Baseline DAS28 was significantly associated with response at 12 months (OR: 1.87, 95%CI: 1.06–3.30, p-value 0.028). In second-line patients, response to tofacitinib was not related to number of biologic DMARDs previously used. CONCLUSION: Tofacitinib is an effective treatment option for patients with RA, maybe better after conventional DMARDs than after biologic therapy failure. Further studies are required to determine the role of tofacitinib in different lines of RA treatment and in other groups of patients. |
format | Online Article Text |
id | pubmed-9289171 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-92891712022-07-19 Is Tofacitinib Effectiveness in Patients with Rheumatoid Arthritis Better After Conventional Than After Biological Therapy? – A Cohort Study in a Colombian Population Santos-Moreno, Pedro Martinez, Susan Ibata, Linda Villarreal, Laura Rodríguez-Florido, Fernando Rivero, Manuel Rojas-Villarraga, Adriana Galarza-Maldonado, Claudio Biologics Original Research PURPOSE: Tofacitinib is recommended for treatment of rheumatoid arthritis (RA) in patients with moderate to severe disease activity, but there is not enough evidence on its effectiveness after conventional DMARDs vs its use after biologics. The aim was evaluating the effectiveness of tofacitinib in RA as first-line treatment (after conventional DMARDs) in a real-life setting in Colombian (Latin-American) patients. PATIENTS AND METHODS: Retrospective cohort study conducted at a specialized center for RA management. A complete statistical analysis was performed to compare the values of the change in the DAS28 at months 3, 6, and 12 in both treatment groups. RESULTS: A total of 152 RA patients who received tofacitinib: first-line 85 patients (55.9%) after failure on conventional DMARDs or second-line 67 patients (44.1%) after failure on biologic DMARDs. Comparative analysis of response to treatment showed a reduction in DAS28 at 3, 6, and 12 months in both study groups without statistical differences, but a higher proportion of first-line patients achieved remission (45% vs 23%). Nonresponse at three months were associated with no response at six months of follow-up. Baseline DAS28 was significantly associated with response at 12 months (OR: 1.87, 95%CI: 1.06–3.30, p-value 0.028). In second-line patients, response to tofacitinib was not related to number of biologic DMARDs previously used. CONCLUSION: Tofacitinib is an effective treatment option for patients with RA, maybe better after conventional DMARDs than after biologic therapy failure. Further studies are required to determine the role of tofacitinib in different lines of RA treatment and in other groups of patients. Dove 2022-07-13 /pmc/articles/PMC9289171/ /pubmed/35860386 http://dx.doi.org/10.2147/BTT.S361164 Text en © 2022 Santos-Moreno et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Santos-Moreno, Pedro Martinez, Susan Ibata, Linda Villarreal, Laura Rodríguez-Florido, Fernando Rivero, Manuel Rojas-Villarraga, Adriana Galarza-Maldonado, Claudio Is Tofacitinib Effectiveness in Patients with Rheumatoid Arthritis Better After Conventional Than After Biological Therapy? – A Cohort Study in a Colombian Population |
title | Is Tofacitinib Effectiveness in Patients with Rheumatoid Arthritis Better After Conventional Than After Biological Therapy? – A Cohort Study in a Colombian Population |
title_full | Is Tofacitinib Effectiveness in Patients with Rheumatoid Arthritis Better After Conventional Than After Biological Therapy? – A Cohort Study in a Colombian Population |
title_fullStr | Is Tofacitinib Effectiveness in Patients with Rheumatoid Arthritis Better After Conventional Than After Biological Therapy? – A Cohort Study in a Colombian Population |
title_full_unstemmed | Is Tofacitinib Effectiveness in Patients with Rheumatoid Arthritis Better After Conventional Than After Biological Therapy? – A Cohort Study in a Colombian Population |
title_short | Is Tofacitinib Effectiveness in Patients with Rheumatoid Arthritis Better After Conventional Than After Biological Therapy? – A Cohort Study in a Colombian Population |
title_sort | is tofacitinib effectiveness in patients with rheumatoid arthritis better after conventional than after biological therapy? – a cohort study in a colombian population |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289171/ https://www.ncbi.nlm.nih.gov/pubmed/35860386 http://dx.doi.org/10.2147/BTT.S361164 |
work_keys_str_mv | AT santosmorenopedro istofacitinibeffectivenessinpatientswithrheumatoidarthritisbetterafterconventionalthanafterbiologicaltherapyacohortstudyinacolombianpopulation AT martinezsusan istofacitinibeffectivenessinpatientswithrheumatoidarthritisbetterafterconventionalthanafterbiologicaltherapyacohortstudyinacolombianpopulation AT ibatalinda istofacitinibeffectivenessinpatientswithrheumatoidarthritisbetterafterconventionalthanafterbiologicaltherapyacohortstudyinacolombianpopulation AT villarreallaura istofacitinibeffectivenessinpatientswithrheumatoidarthritisbetterafterconventionalthanafterbiologicaltherapyacohortstudyinacolombianpopulation AT rodriguezfloridofernando istofacitinibeffectivenessinpatientswithrheumatoidarthritisbetterafterconventionalthanafterbiologicaltherapyacohortstudyinacolombianpopulation AT riveromanuel istofacitinibeffectivenessinpatientswithrheumatoidarthritisbetterafterconventionalthanafterbiologicaltherapyacohortstudyinacolombianpopulation AT rojasvillarragaadriana istofacitinibeffectivenessinpatientswithrheumatoidarthritisbetterafterconventionalthanafterbiologicaltherapyacohortstudyinacolombianpopulation AT galarzamaldonadoclaudio istofacitinibeffectivenessinpatientswithrheumatoidarthritisbetterafterconventionalthanafterbiologicaltherapyacohortstudyinacolombianpopulation |